Clinical Trials Logo

Hypertrophy clinical trials

View clinical trials related to Hypertrophy.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06461468 Not yet recruiting - Clinical trials for Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy Federated Learning Implementation Platform

HCM FLIP
Start date: June 2024
Phase:
Study type: Observational

HCM FLIP study is a two-phase protocol focusing on the detection of Hypertrophic Cardiomyopathy using Electrocardiograms and Echocardiograms through Federated Learning.

NCT ID: NCT06433050 Not yet recruiting - Clinical trials for Hypertrophic Cardiomyopathy Without Obstruction

Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy

SOTA-CROSS HCM
Start date: September 2024
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to learn if sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, works to treat symptomatic, nonobstructive hypertrophic cardiomyopathy (noHCM) in adult patients. It will also learn about the safety of sotagliflozin in this patient population. The main questions it aims to answer are: 1. Will sotagliflozin be well tolerated in patients with nonobstructive HCM? 2. Will sotaglifozin improve exercise capacity, diastolic dysfunction and/or physical functioning in patients with nonobstructive HCM? 3. Will sotagliflozin improve circulating markers of cardiac metabolism in patients with nonobstructive HCM? Researchers will compare sotagliflozin to a placebo (a look-alike substance that contains no drug) to see if sotagliflozin is effective at treating hypertrophic cardiomyopathy (HCM). Participants will: Take sotagliflozin or a placebo every day for 12 weeks. They will then cross-over (or switch) to taking placebo or sotagliflozin (whichever one they did not take initially) for an additional 12 weeks. Visit the clinic once every 4-12 weeks for checkups, surveys, and tests including a stress test and echocardiogram.

NCT ID: NCT06424860 Not yet recruiting - Clinical trials for Cardiovascular Disease

Fish Oil, Metformin and Heart Health in PCOS

Start date: August 1, 2024
Phase: Phase 1
Study type: Interventional

Women with Polycystic Ovary Syndrome (PCOS) have high testosterone levels which is associated with altered insulin-glucose metabolism and an adverse blood lipid profile, predisposing them to the development of Type II Diabetes and Cardiovascular Disease (CVD). This study will investigate the use of dietary fish oil supplementation as a safe and effective intervention, and as an adjunct therapy to standard of care treatment with metformin to improve heart health, blood lipids and insulin-glucose metabolism in women with PCOS, and those with PCOS and Type 2 Diabetes.

NCT ID: NCT06412666 Not yet recruiting - Pediatric Clinical Trials

A Study to Evaluate the Effect of Aficamten in Pediatric Patients (Age 12 to <18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

CEDAR-HCM
Start date: May 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

NCT ID: NCT06408766 Not yet recruiting - Clinical trials for Smartphone Addiction

Investigating the Effects of Smartphone Use on the Masseter Muscle

Start date: May 30, 2024
Phase:
Study type: Observational

The aim of this study was to determine the short- and long-term effects of smartphone use on the masseter muscle. In the short term, to investigate whether repetitive thumb movements during phone use will cause a spontaneous muscle activation and/or tenderness in the masseter muscle; in the long term, to investigate the relationship between strength change and tenderness of the tenar and masseter muscles depending on the intensity and duration of phone use.

NCT ID: NCT06376383 Not yet recruiting - Clinical trials for Obstructive Sleep Apnea

Tonsillectomy vs. Tonsillotomy in Adults With Obstructive Sleep Apnea

Start date: January 2025
Phase: N/A
Study type: Interventional

The primary purpose of this randomized controlled trial s to investigate whether surgical reduction of palatine tonsils (tonsillotomy) is a superior treatment compared to complete surgical removal of palatine tonsils (tonsillectomy) in adults patients with obstructive sleep apnea and concomitant enlarged tonsils in regards of perioperative and postoperative morbidity.

NCT ID: NCT06368037 Not yet recruiting - Clinical trials for Obstructive Hypertrophic Cardiomyopathy

Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy

Start date: August 2024
Phase: N/A
Study type: Interventional

This study is a prospective, single-center, single-group design exploratory clinical research. No control group is set, and only subjects meeting the indications of the study device are treated. After patients sign informed consent, they are screened, and those meeting the inclusion criteria are enrolled. The treatment involves using myocardial radiofrequency ablation system and catheter-based myocardial radiofrequency ablation needle and its guidance system for treating obstructive hypertrophic cardiomyopathy. All subjects are followed up before discharge, and at 30 days, 3 months, 6 months, and 12 months postoperatively.

NCT ID: NCT06269640 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

Start date: June 26, 2024
Phase: N/A
Study type: Interventional

Background: Some people have a condition in which the wall (septum) that separates the two main pumping chambers of the heart is too thick. This thick septum causes a condition called "left ventricular outflow tract obstruction" (LVOTO), which reduces blood flow out of the heart. LVOTO can cause serious heart disease; symptoms may include shortness of breath, chest pain, heart failure, or death. Researchers want to find better ways to treat LVOTO. Objective: To test a new procedure where excess tissue is sliced away from the septum in people with LVOTO. This procedure is called "septal scoring along midline endocardium" (SESAME). Eligibility: Adults aged 21 years with LVOTO. Design: Participants will have baseline tests. They will have imaging scans and tests of their heart structure and function. They will take a walking test and answer questions about how their heart condition affects their life. Participants will stay in the hospital 2 to 6 days for the SESAME procedure. They will be completely or partially asleep for the procedure. A tube will be inserted into the mouth and down the throat to take pictures of the heart. Pictures may also be taken with a tube inserted inside the heart. Next, tubes will be inserted into the groin and guided through the blood vessels up to the heart. Guidewires will be inserted into the heart. Doctors will watch the path the wires take with x-rays and ultrasound. When the wire is in the correct place, it will be electrified to slice excess tissue away from the septum. Participants will have 3 follow-up visits within 1 year....

NCT ID: NCT06164249 Not yet recruiting - Resistance Training Clinical Trials

Quantification of Internal Training Load

QUADRATURE
Start date: January 29, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to determine whether the distribution of internal load predicts the distribution of muscle hypertrophy among hamstring heads after a 10-week resistance exercise program. The hypothesis is that the distribution of internal muscle load among the hamstring is related to the distribution of muscle hypertrophy.

NCT ID: NCT06146660 Not yet recruiting - Clinical trials for Obstructive Hypertrophic Cardiomyopathy

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Start date: June 30, 2024
Phase:
Study type: Observational

The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.